Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; iron oxide yellow; stearic acid; titanium dioxide; lactose; purified water; gelatin; sodium starch glycollate; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - tafamidis as meglumine - capsules soft gelatin - tafamidis as meglumine 12.2 mg - tafamidis - for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; iron oxide yellow; stearic acid; titanium dioxide; lactose; purified water; gelatin; sodium starch glycollate; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - galantamine hydrobromide - oral solution - 4 milligram(s)/millilitre - anticholinesterases; galantamine

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - galantamine hydrobromide - prolonged-release capsule, hard - 16 milligram(s) - anticholinesterases; galantamine

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - galantamine - prolonged-release capsule, hard - 24 milligram(s) - anticholinesterases; galantamine

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - galantamine hydrobromide - prolonged-release capsule, hard - 8 milligram(s) - anticholinesterases; galantamine

Malta - English - Medicines Authority

takeda pharmaceuticals international ag ireland branch block 2 miesian plaza 50 – 58 baggot street lower dublin 2 d02 hw68, ireland - gastro-resistant tablet prolonged-release tablet - mesalazine 1200 mg - antidiarrheals, intestinal antiinflammatory/antiinfective agents

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus infections - antivirals for systemic use - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot).consideration should be given to official guidance on the appropriate use of antiviral agents.